Molecular Devices 3D biology portfolio

Molecular Devices believes in the promise of 3D cell models to advance next-generation drug discovery. Pioneering a future of drug discovery rooted in 3D biology should empower researchers to personalise therapies, reduce a medicine’s time to market and enhance quality of life for patients around the world.

Whether scientists are making the transition from 2D to 3D cell culture for the first time, scaling their organoid development program or integrating a fully automated screening workflow, Molecular Devices is available to help. The company’s robust portfolio of end-to-end high-throughput solutions, user-friendly AI-powered data analysis and committed 3D biotechnology investments should support users in overcoming all their 3D biology challenges.

The company’s organoid line expansion service provides large volumes of standardised, reproducible assay-ready organoids so users can start with confidence. The organisation also delivers fully customised automation solutions for an end-to-end, high-throughput screening workflow.

Molecular Devices offers high-throughput, high-content confocal imaging solutions to obtain high-quality images quickly. Its AI/ML data analysis software meanwhile empowers users with easy-to-use, AI-powered data analysis to turn their images into actionable data.